Materialise Reports Third Quarter 2021 Results
Materialise NV (NASDAQ:MTLS) reported a strong performance for Q3 2021, with total revenue increasing by 28% to 52,195 kEUR compared to 40,785 kEUR in the prior year. Adjusted EBITDA rose 62% to 9,739 kEUR, reflecting improved efficiency. Net profit surged to 8,652 kEUR from a loss of (282) kEUR in Q3 2020. Notably, cash and cash equivalents reached 194,946 kEUR, with a net cash position of 92,766 kEUR. The company anticipates 2021 revenues to be at the upper end of 197,000 kEUR to 200,000 kEUR.
- Total revenue increased 28% to 52,195 kEUR from 40,785 kEUR in Q3 2020.
- Adjusted EBITDA rose 62% to 9,739 kEUR, with an EBITDA margin increase to 18.7%.
- Net profit reached 8,652 kEUR, compared to a net loss of (282) kEUR in Q3 2020.
- Cash and cash equivalents improved to 194,946 kEUR, contributing to a net cash position of 92,766 kEUR.
- Materialise Medical segment's EBITDA decreased to 5,251 kEUR from 5,476 kEUR, with a margin drop to 27.8%.
LEUVEN,
Highlights – Third Quarter 2021
-
Total revenue increased
28% to 52,195 kEUR for the third quarter of 2021 from 40,785 kEUR for the 2020 period. -
Total deferred revenues from annual software sales and maintenance fees increased 547 kEUR to 30,789 kEUR compared to
December 31, 2020 . -
Adjusted EBITDA increased
62% to 9,739 kEUR for the third quarter of 2021 from to 6,023 kEUR for the 2020 period. -
Net profit for the third quarter of 2021 was 8,652 kEUR, or
0.15 EUR per diluted share, compared to a loss of (282) kEUR, or(0.01) EUR per diluted share, for the 2020 period. - Total cash was 194,946 kEUR at the end of the quarter.
Executive Chairman
Third Quarter 2021 Results
Total revenue for the third quarter of 2021 increased
Revenue from our
Revenue from our Materialise Medical segment increased
Revenue from our Materialise Manufacturing segment increased
Gross profit was 31,076 kEUR, an increase of
Research and development (“R&D”), sales and marketing (“S&M”) and general and administrative (“G&A”) expenses increased, in the aggregate,
Net other operating income was 355 kEUR compared to 1,157 kEUR for the third quarter of 2020. Operating result increased to 4,529 kEUR from 284 kEUR for the third quarter of 2020. Net financial result was 4,204 kEUR compared to (1,331) kEUR for the third quarter of 2020. The third quarter of 2021 contained income tax expenses of (80) kEUR, compared to 764 kEUR in the third quarter of 2020.
As a result of the above, our net result for the third quarter of 2021 increased 8,934 kEUR to a net profit of 8,652 kEUR, compared to a net loss of (282) kEUR for the same period in 2020. Total comprehensive income for the third quarter of 2021, which includes exchange differences on translation of foreign operations, was 8,267 kEUR compared to (1,659) kEUR for the 2020 period.
At
Cash flow from operating activities for the first three quarters of 2021 was 17,490 kEUR compared to 14,752 kEUR for the same period in 2020. Total capital expenditures for the third quarter of 2021 amounted to 3,252 kEUR.
Net shareholders’ equity at
2021 Guidance
Non-IFRS Measures
Materialise uses EBITDA and Adjusted EBITDA as supplemental financial measures of its financial performance. EBITDA is calculated as net profit plus income taxes, financial expenses (less financial income), shares of profit or loss in a joint venture and depreciation and amortization. Adjusted EBITDA is determined by adding share-based compensation expenses, acquisition-related expenses of business combinations, impairments and revaluation of fair value due to business combinations to EBITDA. Management believes these non-IFRS measures to be important measures as they exclude the effects of items which primarily reflect the impact of long-term investment and financing decisions, rather than the performance of the company’s day-to-day operations. As compared to net profit, these measures are limited in that they do not reflect the periodic costs of certain capitalized tangible and intangible assets used in generating revenues in the company’s business, or the charges associated with impairments. Management evaluates such items through other financial measures such as capital expenditures and cash flow provided by operating activities. The company believes that these measurements are useful to measure a company’s ability to grow or as a valuation measurement. The company’s calculation of EBITDA and Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. EBITDA and Adjusted EBITDA should not be considered as alternatives to net profit or any other performance measure derived in accordance with IFRS. The company’s presentation of EBITDA and Adjusted EBITDA should not be construed to imply that its future results will be unaffected by unusual or non-recurring items.
Exchange Rate
This document contains translations of certain euro amounts into
Conference Call and Webcast
Materialise will hold a conference call and simultaneous webcast to discuss its financial results for the third quarter of 2021 on
-
To access the conference call, please dial 844-469-2530 (
U.S. ) or 765-507-2679 (international), 4294784#.
The conference call will also be broadcast live over the Internet with an accompanying slide presentation, which can be accessed on the company’s website at http://investors.materialise.com. A webcast of the conference call will be archived on the company's website for one year.
About Materialise
Materialise incorporates 30 years of 3D printing experience into a range of software solutions and 3D printing services, which form the backbone of the 3D printing industry. Materialise’s open and flexible solutions enable players in a wide variety of industries, including healthcare, automotive, aerospace, art and design, and consumer goods, to build innovative 3D printing applications that aim to make the world a better and healthier place. Headquartered in
Cautionary Statement on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, our intentions, beliefs, assumptions, projections, outlook, analyses or current expectations, plans, objectives, strategies and prospects, both financial and business, including statements concerning, among other things, our current estimates for fiscal 2021 revenues and Adjusted EBITDA, results of operations, cash needs, capital expenditures, expenses, financial condition, liquidity, prospects, growth and strategies (including how our business, results of operations and financial condition could be impacted by the COVID-19 pandemic and related public health measures, as well as the related actions we are taking in response), and the trends and competition that may affect the markets, industry or us. Such statements are subject to known and unknown uncertainties and risks. When used in this press release, the words “estimate,” “expect,” “anticipate,” “project,” “plan,” “intend,” “believe,” “forecast,” “will,” “may,” “could,” “might,” “aim,” “should,” and variations of such words or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the expectations of management under current assumptions at the time of this press release. These expectations, beliefs and projections are expressed in good faith and the company believes there is a reasonable basis for them. However, the company cannot offer any assurance that our expectations, beliefs and projections will actually be achieved. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change, and depend on economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We caution you that forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. All of the forward-looking statements are subject to risks and uncertainties that may cause the company's most recent actual results to differ materially from our expectations, including risk factors described in the company's most recent annual report on Form 20-F filed with the
The company is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise, unless it has obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.
Consolidated income statements (Unaudited) |
||||||||||
for the three months ended |
for the nine months ended |
|||||||||
In 000€ | 2021 |
2021 |
2020 (*) |
2021 |
2020 |
|||||
U.S.$ | € | € | € | € | ||||||
Revenue | 60,437 |
52,195 |
40,785 |
148,461 |
125,148 |
|||||
Cost of Sales | (24,454) |
(21,119) |
(17,483) |
(64,378) |
(57,310) |
|||||
Gross Profit | 35,983 |
31,076 |
23,303 |
84,084 |
67,838 |
|||||
Gross profit as % of revenue |
|
|
|
|
|
|||||
Research and development expenses | (7,644) |
(6,602) |
(5,861) |
(19,982) |
(18,434) |
|||||
Sales and marketing expenses | (14,373) |
(12,413) |
(11,015) |
(35,730) |
(33,700) |
|||||
General and administrative expenses | (9,130) |
(7,885) |
(7,300) |
(23,449) |
(21,100) |
|||||
Net other operating income (expenses) | 411 |
355 |
1,157 |
2,318 |
2,733 |
|||||
Operating (loss) profit | 5,247 |
4,529 |
284 |
7,239 |
(2,663) |
|||||
Financial expenses | 2,703 |
2,334 |
(2,462) |
(3,182) |
(4,923) |
|||||
Financial income | 2,164 |
1,869 |
1,132 |
4,426 |
1,976 |
|||||
Share in loss of joint venture | - |
- |
- |
- |
(39) |
|||||
(Loss) profit before taxes | 10,114 |
8,732 |
(1,046) |
8,483 |
(5,649) |
|||||
Income Taxes | (93) |
(80) |
764 |
(55) |
497 |
|||||
Net (loss) profit for the period | 10,021 |
8,652 |
(282) |
8,428 |
(5,152) |
|||||
Net (loss) profit attributable to: | - |
|||||||||
The owners of the parent | 10,022 |
8,655 |
(246) |
8,432 |
(4,989) |
|||||
Non-controlling interest | (3) |
(3) |
(36) |
(4) |
(163) |
|||||
Earning per share attributable to owners of the parent | ||||||||||
Basic | 0.17 |
0.15 |
(0.01) |
0.15 |
(0.01) |
|||||
Diluted | 0.17 |
0.15 |
(0.01) |
0.15 |
(0.01) |
|||||
Weighted average basic shares outstanding | 58,731 |
58,731 |
53,194 |
55,935 |
53,194 |
|||||
Weighted average diluted shares outstanding | 58,944 |
58,944 |
53,194 |
56,206 |
53,194 |
(*) | The year 2020 has been restated to reflect the final accounting of the business combination with Engimplan. | |
Impact on the quarter operating result was 83 kEUR, no impact on year to date operating result. |
Consolidated statements of comprehensive income (Unaudited) |
||||||||||
for the three months ended |
for the nine months ended |
|||||||||
In 000€ | 2021 |
2021 |
2020 (*) |
2021 |
2020 |
|||||
U.S.$ | € | € | € | € | ||||||
Net profit (loss) for the period | 10,021 |
8,652 |
(282) |
8,428 |
(5,152) |
|||||
Other comprehensive income | ||||||||||
Recycling | ||||||||||
Exchange difference on translation of foreign operations | (446) |
(385) |
(1,377) |
1,590 |
(8,165) |
|||||
Non-recycling | ||||||||||
Fair value adjustments through OCI - Equity instruments | - |
- |
- |
48 |
- |
|||||
Other comprehensive income (loss), net of taxes | (446) |
(385) |
(1,377) |
1,638 |
(8,165) |
|||||
Total comprehensive income (loss) for the year, net of taxes | 9,572 |
8,267 |
(1,659) |
10,066 |
(13,317) |
|||||
Total comprehensive income (loss) attributable to: | ||||||||||
The owners of the parent | 9,576 |
8,270 |
(1,490) |
10,069 |
(11,968) |
|||||
Non-controlling interests | (3) |
(3) |
(169) |
(3) |
(1,349) |
(*) | The year 2020 has been restated to reflect the final accounting of the business combination with Engimplan. |
|
Impact on the quarter operating result was 83 kEUR, no impact on year to date operating result. |
Consolidated statement of financial position (Unaudited) |
||||
As of September 30, |
As of December 31, |
|||
In 000€ | 2021 |
2020 |
||
Assets | ||||
Non-current assets | ||||
20,531 |
20,342 |
|||
Intangible assets | 31,534 |
32,981 |
||
Property, plant & equipment | 84,512 |
88,267 |
||
Right-of-Use assets | 9,109 |
10,996 |
||
Investments in joint ventures | - |
- |
||
Deferred tax assets | 249 |
201 |
||
Other non-current assets | 13,868 |
14,139 |
||
Total non-current assets | 159,803 |
166,926 |
||
Current assets | ||||
Inventories | 11,812 |
10,043 |
||
Trade receivables | 38,543 |
30,871 |
||
Other current assets | 9,767 |
8,290 |
||
Cash and cash equivalents | 194,946 |
111,538 |
||
Total non-current assets | 255,068 |
160,741 |
||
Total assets | 414,871 |
327,667 |
As of September 30, |
As of December 31, |
|||
In 000€ | 2021 |
2020 |
||
Equity and liabilities | ||||
Equity | ||||
Share capital | 4,445 |
4,096 |
||
Share premium | 226,750 |
141,274 |
||
Consolidated reserves | 3,430 |
(4,469) |
||
Other comprehensive income | (6,158) |
(7,797) |
||
Equity attributable to the owners of the parent | 228,467 |
133,104 |
||
Non-controlling interest | 7 |
- |
||
Total equity | 228,474 |
133,104 |
||
Non-current liabilities | ||||
Loans & borrowings | 75,760 |
90,502 |
||
Lease liabilities | 5,445 |
7,086 |
||
Deferred tax liabilities | 6,175 |
6,805 |
||
Deferred income | 4,812 |
5,327 |
||
Other non-current liabilities | 2,151 |
398 |
||
Total non-current liabilities | 94,343 |
110,118 |
||
Current liabilities | ||||
Loans & borrowings | 17,740 |
13,984 |
||
Lease liabilities | 3,235 |
3,538 |
||
Trade payables | 22,357 |
17,698 |
||
Tax payables | 1,311 |
974 |
||
Deferred income | 30,174 |
29,554 |
||
Other current liabilities | 17,237 |
18,697 |
||
Total current liabilities | 92,054 |
84,445 |
||
Total equity and liabilities | 414,871 |
327,667 |
Consolidated statement of cash flows (Unaudited) |
||||
for the nine months ended |
||||
In 000€ | 2021 |
2020 |
||
Operating activities | ||||
Net (loss) profit for the period | 8,429 |
(5,153) |
||
Non-cash and operational adjustments | ||||
Depreciation of property plant & equipment | 11,460 |
11,266 |
||
Amortization of intangible assets | 3,780 |
3,349 |
||
Share-based payment expense | (878) |
- |
||
Loss (gain) on disposal of property, plant & equipment | 43 |
(16) |
||
Movement in provisions | 7 |
- |
||
Movement reserve for bad debt | 154 |
36 |
||
Financial income | (4,426) |
(1,977) |
||
Financial expense | 3,182 |
4,922 |
||
Impact of foreign currencies | 107 |
18 |
||
Share in loss (gain) of a joint venture (equity method) | - |
39 |
||
(Deferred) income taxes | 55 |
(496) |
||
Other non-current liabilities | - |
|||
Working capital adjustments | (4,531) |
5,221 |
||
Decrease (increase) in trade receivables and other receivables | (7,553) |
6,765 |
||
Decrease (increase) in inventories | (1,770) |
2,757 |
||
Increase (decrease) in trade payables and other payables | 4,792 |
(4,301) |
||
Income tax paid & Interest received | 108 |
(2,457) |
||
Net cash flow from operating activities | 17,490 |
14,752 |
for the nine months ended |
||||
In 000€ | 2021 |
2020 |
||
Investing activities | ||||
Purchase of property, plant & equipment | (4,827) |
(8,196) |
||
Purchase of intangible assets | (2,439) |
(5,783) |
||
Proceeds from the sale of property, plant & equipment & intangible assets (net) | 295 |
150 |
||
(Convertible) Loan to third party | 1,239 |
(2,428) |
||
Investment in subsidiary, net of cash acquired | (1,680) |
- |
||
Net cash flow used in investing activities | (7,412) |
(16,257) |
||
Financing activities | ||||
Repayment of loans & borrowings | (11,169) |
(8,909) |
||
Repayment of finance leases | (2,841) |
(2,997) |
||
Capital increase | 85,787 |
140 |
||
Interest paid | (1,652) |
(1,626) |
||
Other financial income (expense) | 2,740 |
(1,034) |
||
Net cash flow from (used in) financing activities | 72,865 |
(14,426) |
||
Net increase of cash & cash equivalents | 82,943 |
(15,931) |
||
Cash & Cash equivalents at the beginning of the year | 111,538 |
128,897 |
||
Exchange rate differences on cash & cash equivalents | 465 |
(2,275) |
||
Cash & cash equivalents at end of the year | 194,946 |
110,691 |
Reconciliation of Net Profit (Loss) to EBITDA and Adjusted EBITDA (Unaudited) |
||||||||
for the three months ended |
for the nine months ended |
|||||||
In 000€ | 2021 |
2020 (*) |
2021 |
2020 |
||||
Net profit (loss) for the period | 8,652 |
(282) |
8,428 |
(5,152) |
||||
Income taxes | 80 |
(764) |
55 |
(497) |
||||
Financial expenses | (2,334) |
2,462 |
3,182 |
4,923 |
||||
Financial income | (1,869) |
(1,131) |
(4,426) |
(1,976) |
||||
Depreciation and amortization | 5,314 |
4,839 |
15,240 |
14,616 |
||||
Share in loss of joint venture | - |
- |
- |
39 |
||||
EBITDA | 9,843 |
5,123 |
22,480 |
11,952 |
||||
Share-based compensation expense (1) | (104) |
900 |
(878) |
1,057 |
||||
Acquisition-related expenses business combinations (2) | - |
- |
405 |
- |
||||
Adjusted EBITDA | 9,739 |
6,023 |
22,007 |
13,009 |
(1) | Share-based compensation expense represents the cost of equity-settled and share-based payments to employees. |
|
(2) | Acquisition-related expenses of business combinations represent expenses incurred in connection with the acquisition of our option to buy Link3D. |
|
(*) | The year 2020 has been restated to reflect the final accounting of the business combination with Engimplan. |
|
Impact on the quarter operating result was 83 kEUR, no impact on year to date operating result. |
Segment P&L (Unaudited) |
||||||||||||
In 000€ | Materialise Software |
Materialise Medical |
Materialise Manufacturing |
Total segments |
Unallocated (1)(2) |
Consolidated | ||||||
For the three months ended |
||||||||||||
Revenues | 10,468 |
18,910 |
22,817 |
52,196 |
(0) |
52,195 |
||||||
Segment (adj) EBITDA | 3,708 |
5,251 |
3,546 |
12,506 |
(2,767) |
9,739 |
||||||
Segment (adj) EBITDA % |
|
|
|
|
|
|||||||
For the three months ended |
||||||||||||
Revenues | 9,478 |
17,161 |
14,154 |
40,793 |
(8) |
40,785 |
||||||
Segment (adj) EBITDA | 3,114 |
5,476 |
(321) |
8,269 |
(2,246) |
6,023 |
||||||
Segment (adj) EBITDA % |
|
|
- |
|
|
|||||||
In 000€ | Materialise Software |
Materialise Medical |
Materialise Manufacturing |
Total segments |
Unallocated (1)(2) |
Consolidated | ||||||
For the nine months ended |
||||||||||||
Revenues | 30,719 |
52,686 |
65,199 |
148,604 |
(142) |
148,461 |
||||||
Segment (adj) EBITDA | 10,266 |
14,313 |
5,252 |
29,831 |
(7,826) |
22,004 |
||||||
Segment (adj) EBITDA % |
|
|
|
|
|
|||||||
For the nine months ended |
||||||||||||
Revenues | 28,839 |
44,541 |
51,746 |
125,126 |
21 |
125,147 |
||||||
Segment (adj) EBITDA | 9,515 |
9,072 |
1,447 |
20,035 |
(7,026) |
13,008 |
||||||
Segment (adj) EBITDA % |
|
|
|
|
|
(1) | Unallocated Revenues consists of occasional one-off sales in our core competencies not allocated to any of our segments. |
|
(2) |
Unallocated segment adjusted EBITDA consists of corporate research and development, corporate headquarter costs and corporate other operating income (expense), and the added share-based compensation expenses, acquisition related expenses of business combinations, impairments and fair value of business combinations that are included in Adjusted EBITDA. |
Reconciliation of Net Profit (Loss) to Segment EBITDA (Unaudited) |
||||||||
for the three months ended |
for the nine months ended |
|||||||
In 000€ | 2021 |
2020 (*) |
2021 |
2020 |
||||
Net profit (loss) for the period | 8,652 |
(282) |
8,428 |
(5,152) |
||||
Income taxes | 80 |
(764) |
55 |
(497) |
||||
Financial cost | (2,334) |
2,462 |
3,182 |
4,923 |
||||
Financial income | (1,869) |
(1,131) |
(4,426) |
(1,976) |
||||
Share in loss of joint venture | - |
39 |
||||||
Operating (loss) profit | 4,529 |
285 |
7,239 |
(2,663) |
||||
Depreciation and amortization | 5,314 |
4,839 |
15,240 |
14,616 |
||||
Corporate research and development | 710 |
666 |
2,191 |
2,034 |
||||
Corporate headquarter costs | 2,463 |
2,969 |
6,907 |
7,862 |
||||
Other operating income (expense) | (511) |
(492) |
(1,745) |
(1,816) |
||||
Segment EBITDA | 12,506 |
8,269 |
29,831 |
20,035 |
(*) | The year 2020 has been restated to reflect the final accounting of the business combination with Engimplan. |
|
Impact on the quarter operating result was 83 kEUR, no impact on year to date operating result. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20211028005098/en/
Investor Relations
LHA
212.838.3777
hfried@lhai.com
Source:
FAQ
What were Materialise's Q3 2021 revenue figures for MTLS?
How did Materialise's Adjusted EBITDA perform in Q3 2021?
What is the net profit reported by Materialise for Q3 2021?
What is the cash position of Materialise as of September 30, 2021?